iomeron 350 mg i/ml injektionsvätska, lösning
omnia läkemedel ab - jomeprol - injektionsvätska, lösning - 350 mg i/ml - jomeprol 714 mg aktiv substans - jomeprol
iomeron 400 mg i/ml injektionsvätska, lösning
bracco imaging spa - jomeprol - injektionsvätska, lösning - 400 mg i/ml - jomeprol 816 mg aktiv substans - jomeprol
elamal 40 mg/g kräm
scharper s.p.a. - lidokain - kräm - 40 mg/g - propylenglykol hjälpämne; bensylalkohol hjälpämne; lidokain 40 mg aktiv substans - lidokain
tixteller 550 mg filmdragerad tablett
alfasigma s.p.a. - rifaximin - filmdragerad tablett - 550 mg - propylenglykol hjälpämne; rifaximin 550 mg aktiv substans - rifaximin
salonpas comp kutan spray, lösning
hisamitsu italia s.r.l. - d-kamfer; hydroxietylsalicylat; levomentol; metylsalicylat - kutan spray, lösning - metylsalicylat 17,5 mg aktiv substans; hydroxietylsalicylat 17,5 mg aktiv substans; d-kamfer 30 mg aktiv substans; levomentol 32 mg aktiv substans - salicylsyraderivat
salonpas comp medicinskt plåster
hisamitsu italia s.r.l. - kamfer, racemisk; levomentol; metylsalicylat - medicinskt plåster - butylhydroxitoluen hjälpämne; levomentol 32,7 mg aktiv substans; metylsalicylat 36,1 mg aktiv substans; kamfer, racemisk 7,1 mg aktiv substans - salicylsyraderivat
salonpas 105 mg/31,5 mg medicinskt plåster
hisamitsu italia s.r.l. - levomentol; metylsalicylat - medicinskt plåster - 105 mg/31,5 mg - metylsalicylat 105 mg aktiv substans; levomentol 31,5 mg aktiv substans - utvärtes medel vid led- och muskelsmärtor
virbagen omega
virbac s.a. - rekombinant omega-interferon av felint ursprung - immunstimulatorer, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. hos katter infekterade av fiv var mortaliteten låg (5%) och påverkades inte av behandlingen.
zalmoxis
molmed spa - allogena t celler genetiskt modifierad med en retrovirala vektor kodning för en stympad form av mänsklig låg affinitet nervtillväxtfaktor receptorn (Δlngfr) och den herpes simplex virus tymidinkinas (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastiska medel - zalmoxis indikeras som tilläggsbehandling vid haploidentisk hematopoetisk stamcellstransplantation (hsct) hos vuxna patienter med högriskhormatiska maligniteter.
teriparatide sun
sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - calciumhomeostas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.